Entera Bio (ENTX) Research & Development (2019 - 2026)

Entera Bio (ENTX) has reported Research & Development for 8 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 100.45% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.1 million (up 45.94% YoY) and the FY2025 annual result came in at $6.0 million, up 33.45% from the prior year.
• Research & Development improved to $2.3 million in Q1 2026 per ENTX's latest filing, from $1.7 million in the prior quarter.
• Over the last five years, Research & Development for ENTX reached as high as $2.3 million in Q1 2026 and fell as low as $735000.0 in Q1 2024.
• A 5-year average of $1.4 million and a median of $1.4 million in 2023 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2022 — Research & Development plunged 49.0% — and 2026, when it jumped 100.45%.
• Year by year, Research & Development stood at $1.4 million in 2022, then fell by 25.98% to $1.0 million in 2023, then climbed by 20.1% to $1.2 million in 2024, then surged by 43.05% to $1.7 million in 2025, then surged by 31.02% to $2.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $2.3 million, $1.7 million, and $1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.